High-dose Bevacizumab in Advanced Renal Carcinoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2013

Study Completion Date

September 30, 2013

Conditions
Renal CancerKidney Cancer
Interventions
DRUG

Bevacizumab

Bevacizumab

Trial Locations (13)

15213

University of Pittsburgh Medical Center, Pittsburgh

20817

Center for Cancer and Blood Disorders, Bethesda

23601

Peninsula Cancer Institute, Newport News

28801

Cancer Care of Western North Carolina, Asheville

29303

Spartanburg Regional Medical Center, Spartanburg

30501

Northeast Georgia Medical Center, Gainesville

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

38017

Family Cancer Center, Collierville

40207

Consultants in Blood Disorders and Cancer, Louisville

45242

Oncology Hematology Care, Cincinnati

68114

Methodist Cancer Center, Omaha

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER